Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HRH3 | Q9Y5N1 | 14/20 | 0.48 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | PKM | P14618 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13319427 | 0.92 | HRH3 (0.43) | HRH3CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13319372 | 0.92 | HRH3 (0.44) | HRH3CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13319370 | 0.90 | HRH3 (0.46) | HRH3CYP3A4CYP2D6SMN1; SMN2CYP2C9 | |
| SCHEMBL14469156 | 0.88 | HRH3 (0.50) | HRH3CYP3A4CYP2D6SMN1; SMN2MAPK1 | |
| SCHEMBL13319282 | 0.87 | CYP3A4 (0.51) | CYP3A4CYP2D6SMN1; SMN2MAPK1 | |
| SCHEMBL13319432 | 0.86 | HRH3 (0.42) | HRH3CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13319437 | 0.86 | HRH3 (0.49) | HRH3CYP3A4CYP2D6SMN1; SMN2MAPK1 | |
| SCHEMBL13319449 | 0.85 | HRH3 (0.43) | HRH3CYP3A4CYP2D6CYP2C9 | |
| SCHEMBL13319275 | 0.84 | HRH3 (0.48) | HRH3CYP3A4CYP2D6CYP2C9ALDH1A1 | |
| SCHEMBL13319206 | 0.84 | HRH3 (0.49) | HRH3CYP3A4CYP2D6CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144591-A1 | BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| US-20100144591-A1 | BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | SCHERING CORPORATION | 2010-06-10 | — | — | US | disclosed |
| WO-2007075555-A2 | COMBINATION OF AN H3 ANTAGONIST/INVERSE AGONIST AND AN APPETITE SUPPRESSANT | SCHERING CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144591-A1 | BENZIMIDAZOLE DERIVATIVES AND METHODS OF USE THEREOF | GPR119, GK, GCK | HRH3 3101/4885CYP3A4 339/4885CYP2D6 293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.